Interestingly although SEMA3F was up-regulated in most of the 16 tested cancer types except in HNSC, LUAD, and PRAD, the increased expression of SEMA3F was generally not associated with overall survival except with survival advantage in KIRC and poor prognosis in GBM, but the correlation studies between SEMA3F expression and immune components, as well as with tumor stemness indicate a tumor promotor role of SEMA3F in tumors. This evidence concerns the gene SEMA3F and neoplasm.